Literature DB >> 21984207

Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets.

Marcel Bruggisser1, Michael Bodmer, Matthias E Liechti.   

Abstract

BACKGROUND: Non-medical use of methylphenidate is increasing. Little is known about potential acute medical complications associated with recreational use of methylphenidate. STUDY AIM: To identify medical problems associated with methylphenidate abuse.
METHODS: Retrospective case series of methylphenidate abuse cases presenting to an inner city emergency department.
RESULTS: We identified 14 cases of methylphenidate abuse between 2003 and 2010. Ten of these patients abused methylphenidate alone while four co-ingested other drugs, mainly alcohol. The route of ingestion was oral in nine patients, nasal in one and intravascular in four. Severe toxicity was exclusively observed in users who injected the drug. Two cases involved accidental intra-arterial injection and resulted in tissue necrosis leading to the amputation of a forearm and of fingertips, respectively. Clinical findings in the non-serious cases included mild to moderate symptoms and signs of sympathetic nervous stimulation such as agitation, tachycardia, hypertension, anxiety, hallucination, headache, tremor and dizziness. Nine of the fourteen patients were taking methylphenidate as a prescribed drug. Eight patients were former or current multiple substance abusers.
CONCLUSION: Methylphenidate misuse is not a significant burden for emergency departments in Switzerland. Oral and nasal administration of methylphenidate did not result in severe toxicity. However, injection of crushed methylphenidate pills lead to serious local toxicity. Most patients with methylphenidate abuse had a prescription for the drug indicating deviation from medical use. A history of multiple substance use may be a risk factor for non-medical use of methylphenidate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984207     DOI: 10.4414/smw.2011.13267

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  8 in total

1.  Characterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit.

Authors:  Suzanne K Vosburg; Rebekkah S Robbins; Kevin M Antshel; Stephen V Faraone; Jody L Green
Journal:  Addict Behav Rep       Date:  2021-09-11

2.  Prescription Stimulant Misuse and Diversion Events Among College Students: A Qualitative Study.

Authors:  Candelaria Garcia; Brian Valencia; Kate Diaz Roldan; Jacquelyn Garcia; Jeovanna Amador Ayala; Alison Looby; Jaimie McMullen; Niloofar Bavarian
Journal:  J Prev (2022)       Date:  2021-11-02

Review 3.  Psychostimulants and movement disorders.

Authors:  Andres Asser; Pille Taba
Journal:  Front Neurol       Date:  2015-04-20       Impact factor: 4.003

Review 4.  Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.

Authors:  Xanthe M Barkla; Paul A McArdle; Dorothy Newbury-Birch
Journal:  BMC Psychiatry       Date:  2015-10-30       Impact factor: 3.630

Review 5.  Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.

Authors:  Rafał R Jaeschke; Ewelina Sujkowska; Magdalena Sowa-Kućma
Journal:  Psychopharmacology (Berl)       Date:  2021-08-26       Impact factor: 4.530

6.  High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report.

Authors:  Michael Liebrenz; Danielle Hof; Anna Buadze; Rudolf Stohler; Dominique Eich
Journal:  J Med Case Rep       Date:  2012-05-14

7.  Acute cocaine-related health problems in patients presenting to an urban emergency department in Switzerland: a case series.

Authors:  Michael Bodmer; Florian Enzler; Evangelia Liakoni; Marcel Bruggisser; Matthias E Liechti
Journal:  BMC Res Notes       Date:  2014-03-25

8.  To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students.

Authors:  Larissa J Maier; Matthias E Liechti; Fiona Herzig; Michael P Schaub
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.